Cybin Inc. (NEO:CYBN)
Canada · Delayed Price · Currency is CAD | Market Cap | 232.44M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -131.93M |
| Shares Out | n/a |
| EPS (ttm) | -6.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,987 |
| Average Volume | 21,145 |
| Open | 8.70 |
| Previous Close | 8.62 |
| Day's Range | 8.27 - 8.70 |
| 52-Week Range | 6.95 - 19.46 |
| Beta | 1.08 |
| RSI | 46.73 |
| Earnings Date | Nov 13, 2025 |
About Cybin
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for M... [Read more]
News
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental h...
Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental h...
Cybin to Participate at the 2025 Milken Institute Future of Health Summit
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental h...
Cybin Announces Closing of $175 Million Registered Direct Offering
TORONTO--(BUSINESS WIRE)--Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) (“Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental...
Cybin Announces $175 Million Registered Direct Offering
TORONTO--(BUSINESS WIRE)--Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) (“Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN). Such investors are advised to contact Danie...
Cybin: Optimism Quickly Fades
Cybin faces clinical trial delays, leadership changes, and cash burn concerns. Learn why CYBN's outlook has been downgraded and what must improve to rebound.
BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor
VANCOUVER, British Columbia, October 21, 2025 – TheNewswire - BetterLife Pharma Inc. (“BetterLife” or the “Compa ny”) ( CSE: BETR / OTCQB : BETRF / FRA: NPAU) , an emerging biotech company, has annou...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN). Such investors are advised to contact Danie...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN). Such investors are advised to contact Danie...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN). Such investors are advised to contact Daniel...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN). Such investors are advised to contact Daniel...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. (“Cybin” or the “Company”) (NYSE: CYBN). Such investors are advised to contact D...
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcar...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK , Sept. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. (“Cybin” or the “Company”) (NYSE: CYBN). Such investors are advised to contact...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK , Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN).
CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $CYBN--CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm.
Cybin to Participate in TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing ...
Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcar...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. (“Cybin” or the “Company”) (NYSE: CYBN). Such investors are advised to contact D...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN).
Cybin (CYBN) Completes Enrollment for Phase 2 Anxiety Disorder Study
Cybin (CYBN) Completes Enrollment for Phase 2 Anxiety Disorder Study